AbCellera (NASDAQ: ABCL) is a clinical-stage antibody discovery company that uses artificial intelligence to rapidly identify best-in-class molecules. It has developed a high throughput microfluidic antibody screening platform which addresses key bottlenecks in antibody discovery to quickly generate the most promising lead compounds. The power of their platform was recently demonstrated through a partnership with Eli Lilly in which they developed bamlanivimab, the premier monoclonal antibody therapy for treatment of COVID-19, in record time (6 weeks between hit to lead; regulatory approval for in 9 months).  We expect AbCellera to continue to produce promising new biologics through their partnerships with the world’s leading pharmaceutical companies including Pfizer, GSK, Gilead and many others.  

No items found.